JP Morgan Keeps Overweight Rating on Olema Pharmaceuticals and Increases Price Target to $32
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 18 2025
0mins
Source: Benzinga
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.
Market Winning Tools: The platform is designed to provide traders with the tools and information necessary to succeed in their market endeavors.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on OLMA
Wall Street analysts forecast OLMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OLMA is 42.00 USD with a low forecast of 20.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 26.060
Low
20.00
Averages
42.00
High
60.00
Current: 26.060
Low
20.00
Averages
42.00
High
60.00
About OLMA
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. It is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Its lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), in a Phase 3 clinical trial called OPERA-01. It is being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In addition, it is developing OP-3136, a potent KAT6 inhibitor, in a Phase 1 clinical trial. OP-3136 is a novel, orally available small molecule that potently and selectively inhibits KAT6.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of OLMA Options Contracts and Investment Opportunities
- Put Option Appeal: The current bid for the $25.00 put option is $4.00, and if an investor sells this contract, their effective purchase price for the stock drops to $21.00, representing a 2% discount from the current price of $25.64, making it attractive for those interested in OLMA shares.
- Yield Potential: Should the put option expire worthless, it would yield a 16% return on the cash commitment, equating to an annualized return of 55.64%, highlighting the potential attractiveness of this investment strategy.
- Call Option Returns: The $26.00 call option has a current bid of $4.60, and if an investor buys OLMA shares at $25.64 and sells this contract, they could achieve a total return of 19.34% if the stock is called away at expiration, showcasing the profit potential of this strategy.
- Risk Assessment: Current analytics indicate a 65% chance that the $25.00 put option will expire worthless, while the $26.00 call option has a 37% chance of doing so, necessitating careful evaluation of the risk-reward balance for investors.
Continue Reading
Glaukos Corp (GKOS) Projects FY25 Sales of $507 Million, Shares Drop 12.1%
- Glaukos Sales Projection: Glaukos Corp anticipates FY25 sales of $507 million, yet its shares fell 12.1% in pre-market trading, indicating market concerns about its growth outlook despite the positive sales forecast.
- Briacell's Sharp Decline: Briacell Therapeutics' announcement of a $30 million public offering led to a staggering 53.1% drop in its stock price during pre-market trading, reflecting investor apprehension regarding the financing strategy.
- Trip.com Investigation Impact: Trip.com Group confirmed it is under investigation by China's SAMR for potential anti-monopoly violations, resulting in a 9.3% decline in its pre-market stock price, which may adversely affect its market performance and investor confidence.
- Pearson Trading Update: Pearson PLC's trading update for 2025 caused its shares to drop 7.2% in pre-market trading, indicating a cautious market sentiment regarding its future performance.
Continue Reading